<DOC>
	<DOCNO>NCT00404612</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy LX211 therapy subject active non-infectious uveitis</brief_summary>
	<brief_title>A Study LX211 Active Sight Threatening , Non-infectious Intermediate- , Anterior Intermediate- , Posterior- , Pan-Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Panuveitis</mesh_term>
	<mesh_term>Uveitis , Posterior</mesh_term>
	<mesh_term>Uveitis , Intermediate</mesh_term>
	<mesh_term>Pars Planitis</mesh_term>
	<criteria>Documented history noninfectious intermediate , anterior intermediate , posterior panuveitis uveitis Current uveitis therapy must conform one following : 1 . Prednisone monotherapy dose ≥ 10 mg/day ( equivalent ) ≥ 2 week prior randomization 2 . Have receive ≥ 2 injection corticosteroid ( intravitreal periocular ) control disease within past 8 month , within 2 week randomization ; subject may also receive systemic corticosteroid therapy 3 . Receiving monotherapy azathioprine , mycophenolate mofetil , mycophenolic acid methotrexate least 2 week prior randomization 4 . Receiving prednisone addition one immunomodulatory agent among cyclosporine , tacrolimus , azathioprine , mycophenolate mofetil , mycophenolic acid methotrexate least 2 week prior randomization 5 . Subjects corticosteroid therapy ( systemic local ) medically inappropriate refuse corticosteroid therapy Grade 2+ high vitreous haze time enrollment Considered investigator require immunomodulatory therapy . Not plan undergo elective ocular surgery study Uveitis infectious etiology Clinically suspect confirmed central nervous system ocular lymphoma Primary diagnosis anterior uveitis</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>uveitis</keyword>
	<keyword>calcineurin</keyword>
</DOC>